Combination immunotherapy for colorectal cancer: Clinical applications, rationale, challenges, and future
Jiang Fei1, Changjing Cai1, Wantao Wu1
1Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Clinical Research Center for Geriatric Disease (Xiangya Hospital), Central South University, Changsha, Hunan 410008, P.R. China.
None:
Colorectal cancer (CRC) is a leading cause of cancer-related mortality. Although immunotherapy has demonstrated remarkable efficacy in deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) tumors, most proficient mismatch repair (pMMR)/microsatellite stability (MSS)/microsatellite instability-low (MSI-L) patients derive limited benefit. Combination strategies-including immune checkpoint inhibitors (ICIs), chemotherapy, targeted therapy, and radiotherapy-offer promise for overcoming resistance. This review examines recent clinical advances in combination immunotherapy for CRC, with a focus on tumor microenvironment (TME) modulation and predictive biomarkers. By bridging preclinical insights and clinical applications, we aim to facilitate the optimization of therapeutic strategies and extend the benefits of immunotherapy across CRC subtypes.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...


